Exciting immunotherapy clinical trials for the management of AMLO_Marion Subklewe_02
Marion Subklewe, MD, from LMU Hospital Munich, Munich, Germany, discusses several clinical trials in acute myeloid leukemia (AML) that are currently underway, including a Phase I trial investigating M...
Author: VJHemOnc
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
The latest clinical trials into novel AML therapies
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the new and exciting clinical trials that are currently underway for the treatment of acute myeloid leukemia (...
Author: VJHemOnc
Added: 06/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Biological rationales when determining AML therapies
Chrisoph Rllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, discusses the rationale behind determining the most suitable treatment for a patient with acute myeloid leukemia ...
Author: VJHemOnc
Added: 06/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Moxetumomab Pasudotox Pivotal in relapse refractory hairy cell leukemia
Michelle Dawson, MD, AstraZeneca, talks about Moxetumomab Pasudotox Pivotal in relapse refractory hairy cell leukemia at ASCO 2018.
Author: Annual-Meeting
Added: 06/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Increasing AML clinical trial participation rates
Despite major advancements in the understanding of the genetic drivers of acute myeloid leukemia (AML) and the pathophysiology of the disease, standard treatment options for AML patients have not expe...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Combining existing drugs for the creation of novel AML therapies
Gail Roboz, MD, from the Weill Medical College of Cornell University, New York City, NY, explores exciting next-generation agents for the treatment of acute myeloid leukemia (AML), such as guadecitabi...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Managing relapse in AML: the role of MRD
Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood counts or examining the morphology of the bone marrow is not suf...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
The complications of treating elderly patients with AML
The average age of people suffering from acute myeloid leukemia (AML) is around 60 to 70 years, and there are many issues surrounding the use of chemotherapy drugs in this population. In this intervie...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
The CAR T-cell therapy race
Unlike childhood acute lymphoblastic leukemia (ALL), there are currently no approved CAR T-cell products for the treatment of adult ALL; here, Noelle Frey, MD, from the University of Pennsylvania, Phi...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
CAR T-cell therapy and ALL: the current landscape
CAR T-cell therapy has proven effective in delivering high response rates in relapsed acute lymphoblastic leukemia (ALL) patients, but what can be done to move the field forward? Here, Noelle Frey, MD...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
The challenges of choosing the right target antigen in AML compared to ALL
Treatment outcomes for acute myeloid leukemia (AML) patients treated with immunotherapy have significantly lagged behind those achieved for acute lymphoblastic leukemia (ALL), and this is due to the f...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Encouraging patients to participate in AML trials
Despite recent approvals of drugs targeting acute myeloid leukemia (AML), overall survival and complete remission rates remain suboptimal. In this interview, Eytan Stein, MD, from the Memorial Sloan K...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Primary and secondary resistance in AML
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the mechanisms of resistance to targeted therapies such as enasidenib and ivosidenib in acute myeloid leukemia...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Toxicity profiles of IDH inhibitors: are they as intimidating as they seem?
The side effects of isocitrate dehydrogenase (IDH) inhibitors for the treatment of acute myeloid leukemia (AML) include gastrointestinal toxicity, leukocytosis, differentiation syndrome and QT prolong...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Managing AML in elderly patients
Traditionally, the standard therapy for the management of acute myeloid leukemia (AML) in elderly patients has been low-dose cytarabine, but hypomethylating agents (HMAs) have quickly become the backb...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
